Table 1.
Patient demographic and clinical characteristics
| Variables | New priming regimens (n=80) | Conventional priming regimens (n=129) | P-value |
|---|---|---|---|
| Age, median (range) | 54 (15–81) | 50 (14–78) | 0.878 |
| Sex, n (%) | |||
| Male | 42 | 69 | 0.889 |
| Female | 38 | 60 | |
| Disease subtype | |||
| AML | 44 | 77 | 0.504 |
| M1 | 4 | 10 | 0.439 |
| M2 | 17 | 28 | 0.938 |
| M4 | 7 | 17 | 0.329 |
| M5 | 16 | 22 | 0.591 |
| MDS | 36 | 52 | 0.504 |
| RAEB | 26 | 34 | 0.340 |
| RAEBT | 10 | 18 | 0.764 |
| Risk stratification | |||
| Low | 5 | 8 | 1.000 |
| Middle | 42 | 66 | 0.851 |
| High | 33 | 55 | 0.844 |
| WBC count (×109/L) | 8.77 (0.6–30) | 9.15 (0.4–32) | 0.449 |
| RBC count (×1012/L) | 2.1 (1.0–5.1) | 2.3 (1.3–4.9) | 0.965 |
| PLT count (×109/L) | 34 (2–121) | 28 (1–101) | 0.898 |
| Myeloblast (%) | 31.17 (5.5–93) | 34.14 (5.5–81) | 0.565 |
| Karyotype t (8; 21) | 26 | 38 | 0.643 |
Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; RAEB, refractory anemia with excess blasts; RAEBT, refractory anemia with excess blasts in transformation; WBC, white blood cell; RBC, red blood cell; PLT, platelet.